Close Menu

More articles about Reproductive Health

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.

The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.

Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.

The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.

Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.

Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.

NYU Winthrop has granted Progenity an exclusive license to patents that it holds covering a biomarker for predicting preterm births.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

Some at-home infectious disease tests and sample collection kits exist in a murky regulatory realm, and their sale to patients is troubling laboratorians and clinicians.

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

The study showed that the Zeesan test kit and qPCR instrument could be used for near-patient HPV typing of 94 samples in 2.5 hours.

The Aptima BV test detects bacterial vaginosis and the Aptima CV/TV detects and differentiates candida infections from trichomonas.

The self-administered test is designed to detect human chorionic gonadotropin levels in women as early as six days before a first missed period.

The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.

The Hologic Aptima Combo 2 and the Cepheid Xpert CT/NG assays have now been cleared for use in throat and rectum samples.

The guidelines, drafted with support from PerkinElmer, calls for universal screening of pregnant women for preterm preeclampsia during the first trimester.

The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.

The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.

Pages